CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The CSL Limited (ASX:CSL) share price is close to a 52-week low, is it a buy?
President elect Joe Biden has revealed a US$1.9 trillion healthcare and economic plan to try to help the Unites States of America.
CSL Limited (ASX:CSL) shares could be an interesting idea for blue chip investors.
Looking for the best Australian shares ETFs of 2021? There are a number of top Australian shares ETFs listed on the ASX which provide varying types and levels of exposure based upon factors such as market capitalisation and dividend yield.
My top 5 ASX ETFs for a diversified portfolio: iShares S&P 500 ETF (ASX: IVV), iShares Core S&P/ASX 200 ETF (ASX: IOZ), BetaShares NASDAQ 100 ETF (ASX: NDQ), Vanguard All-World ex-U.S. Shares Index ETF (ASX: VEU) and Vanguard MSCI Index International Shares ETF (ASX: VGS).
The S&P/ASX 200 (INDEXASX: XJO) is expected to open flat on Monday. CSL Limited (ASX:CSL) and Westpac Banking (ASX:WBC) shares are in the news.
CSL Limited (ASX:CSL) announced some disappointing UQ COVID-19 vaccine news today.
The S&P/ASX 200 (ASX: XJO) is expected to open slightly lower this morning, according to the Sydney Futures Exchange. Here’s what you missed…
The CSL Limited (ASX:CSL) share price could be in danger, if these new vaccines become the new normal way of doing things.
